Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy

Shahgholi, E; Ehsani, Mohammad Ali; Salamati, Payman; Maysamie, Alipasha; Sotoudeh, Kambiz; Mokhtari‐Azad, Talat

doi:10.1002/pbc.22421

Cited by 32 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been conflicting data on the immune response to influenza vaccination in patients with leukemia, despite the fact that patients with leukemia may benefit from influenza vaccine. 4,9 Shahgholi et al 4 reported that immune response of children with ALL during maintenance therapy and that of healthy controls was 43.4% versus 88% for H1N1 (P = 0.04). They concluded that influenza vaccine is well tolerated in ALL patients with acceptable but limited immune response compared with healthy controls.…”

Section: Discussionmentioning

confidence: 97%

“…This is an important issue in the case of children with leukemia who may be more susceptible to complications from H1N1 infection. [1][2][3][4][5] To our knowledge, there are only 2 specific series of H1N1 influenza pandemic in children with leukemia. 2,3 To increase information about pandemic influenza in children with leukemia and to better understand the risk factors for severe disease, we have presented the clinical characteristics of 8 children with acute leukemia and pandemic influenza treated at our center.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pandemic H1N1 Influenza Infection in Children With Acute Leukemia

Tavil

Azık

Culha

et al. 2012

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

In English literature, there are only 2 specific series of pandemic H1N1 influenza infection in children with leukemia. To increase knowledge about pandemic influenza in children with leukemia and better understand the risk factors for severe disease, we have presented the clinical characteristics of 8 children with acute leukemia and pandemic influenza treated at our center. The mean age of the children (4 girls and 4 boys) was 6.7±2.0 years (range, 4 to 10 y). All these children [3 acute lymphoblastic leukemia and 5 acute myeloid leukemia (AML) cases] were receiving chemotherapy during the course of infection, except 1 who was found to be H1N1 positive at the same time that she was diagnosed with AML. Among the other 7 patients undergoing chemotherapy, 4 were receiving induction, 1 was receiving consolidation, and 2 were undergoing maintenance chemotherapy. In our series, 1 patient with AML had a fatal course. She had recently received a chemotherapy bloc. Her neutrophil count was 0 during the course of H1N1 infection. She developed acute respiratory distress syndrome within a short time after the symptoms commenced and she died within 4 days. In conclusion, the clinical course of H1N1 infection may be fatal in rare cases of leukemic children receiving chemotherapy. Thus, vaccination is advisable for all leukemic children, especially for those under maintenance chemotherapy, as it might be life saving during such pandemics.

show abstract

Section: Discussionmentioning

confidence: 97%

mentioning

confidence: 99%

Pandemic H1N1 Influenza Infection in Children With Acute Leukemia

Tavil

Azık

Culha

et al. 2012

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…About protection rate in pre-vaccine children, Shahgholi et al reported a proportion of 11/32 (34%) for H1N1, 7/32 (21.8%)for H3N2, 8/32 (25%) for B with protective titer 32. After vaccination, the pooled prevalence resulted, for H1N1 one dose 59.3%, for H3N2 50%, for B 59.2%.…”

Section: Discussionmentioning

confidence: 99%

Influenza and pneumococcal vaccination in hematological malignancies: a systematic review of efficacy, effectiveness and safety

Torre¹

2016

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

BackgroundThe risk of getting influenza and pneumococcal disease is higher in cancer patients, and serum antibody levels tend to be lower in patients with hematological malignancy.ObjectiveTo assess flu and pneumococcal vaccinations efficacy, effectiveness, and safety in onco-hematological patients.MethodsTwo systematic reviews and possible meta-analysis were conducted to summarize the results of all primary study in the scientific literature about the flu and pneumococcal vaccine in onco-hematological patients. Literature searches were performed using Pub-Med and Scopus databases. StatsDirect 2.8.0 was used for the analysis.Results22 and 26 studies were collected respectively for flu and pneumococcal vaccinations. Protection rate of booster dose was 30% (95% CI=6–62%) for H1N1. Pooled prevalence protection rate of H3N2 and B was available for meta-analysis only for first dose, 42.6% (95% CI=23.2 – 63.3 %) and 39.6 % (95% CI=26%–54.1%) for H3N2 and B, respectively. Response rate of booster dose resulted 35% (95% CI=19.7–51.2%) for H1N1, 23% (95% CI=16.6–31.5%) for H3N2, 29% (95% CI=21.3–37%) for B.ConclusionDespite the low rate of response, flu, and pneumococcal vaccines are worthwhile for patients with hematological malignancies. Patients undergoing chemotherapy in particular rituximab, splenectomy, transplant recipient had lower and impaired response. No serious adverse events were reported for both vaccines.

show abstract

“…[280][281][282] Many of these studies found that a second dose significantly improved the proportion achieving serological protection. Despite decreased levels of protective antibodies, several analyses have found evidence of reduced risk of death following vaccination in immunocompromised cohorts.…”

Section: Disease Burdenmentioning

confidence: 99%

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Rondy¹,

Launay

Puig-Barberà

et al. 2015

Eurosurveillance

View full text Add to dashboard Cite

show abstract

Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy

Abstract: Influenza vaccine is tolerated well in ALL patients with acceptable but limited immune response compared to healthy controls. These findings support the recommendation for annual influenza vaccination in children with ALL.

Cited by 32 publications

References 21 publications

Pandemic H1N1 Influenza Infection in Children With Acute Leukemia

Pandemic H1N1 Influenza Infection in Children With Acute Leukemia

Influenza and pneumococcal vaccination in hematological malignancies: a systematic review of efficacy, effectiveness and safety

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Contact Info

Product

Resources

About